DTX401
DTX401-CL301
Phase 3 gene_therapy completed
Quick answer
DTX401 for Glycogen Storage Disease Type IA is a Phase 3 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Glycogen Storage Disease Type IA
- Phase
- Phase 3
- Modality
- gene_therapy
- Status
- completed